Titre :
|
Home uterine activity monitoring in the prevention monitoring in the prevention of very low birth weight. (1997)
|
Auteurs :
|
A. KEMPE ;
H. RICCIOTTI ;
B.P. SACHS ;
A.M. SOBOL ;
P.H. WISE ;
Beth Israel Deaconess Medical Center. USA ;
Department of Obstetrics and Gynecology and Reproductive Medicine. Harvard Medical School. USA
|
Type de document :
|
Article
|
Dans :
|
Public health reports (vol. 112, n° 5, 1997)
|
Pagination :
|
433-439
|
Langues:
|
Anglais
|
Mots-clés :
|
Surveillance
;
Utérus
;
Grossesse
;
Surveillance domicile
;
Evaluation
;
Homme
;
Femme
;
Prévention santé
;
Etats Unis
;
Amérique du Nord
;
Amérique
;
Gestation [pathologie]
;
Appareil génital femelle
|
Résumé :
|
[BDSP. Notice produite par INIST ZT445R0x. Diffusion soumise à autorisation]. Objectives. Despite controversy regarding the efficacy of home uterine activity monitoring (HUAM), it is currently licensed for detection of preterm labor in women with previous preterm deliveries. In practice, however, it is being more widely utilized in an effort to prevent preterm delivery. This study seeks to determine which group of mothers delivering very low birth weight (VLBW) infants would have qualified for HUAM given three different sets of criteria and in which women it could have been used to help prolong gestation. Methods. The authors reviewed the medical records of mothers of VLBW infants born in five U.S. locations (N=1440), retrospectively applying three sets of eligibility criteria for HUAM use : (a) the current FDA licensing criterion for use of HUAM, a previous preterm birth ; (b) indications for HUAM commonly cited in published reports ; (c) a broad set of criteria based on the presence of any reproductive or medical conditions that might predispose to premature delivery. The authors then analyzed the conditions precipitating delivery for each group to determine whether delivery might have been prevented with HUAM and tocolytic therapy. Results. Only 4.4% of the total group of women delivering VLBW infants would have been eligible for HUAM under the FDA criterion and might potentially have benefited from this technology. (...)
|